Ocrevus

Search results

Bio & Pharma Celltrion gets OK partial approval for phase 3 of biosimilar in Europe

South Korean biopharmaceutical company Celltrion Inc. announced on Tuesday that it has received approval from the European Medicines Agency (EMA) fo...

Aug 22, 2023 (Gmt+09:00)
Bio & Pharma Celltrion wins phase 3 IND approval for Ocrevus biosimilar in US

South Korea's biopharmaceutical company Celltrion Inc. announced that it received on Thursday approval from the US Food and Drug Administration (FDA...

Jun 15, 2023 (Gmt+09:00)
Bio & Pharma Celltrion applies for Phase 3 clinical trials in Europe for biosimilar

South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...

May 03, 2023 (Gmt+09:00)

Cookies on KED Global

We use cookies to provide the best user experience. By continuing to browse this website, you will be considered to accept cookies. Please review our Privacy Policy to learn our cookie policy.

Cookies on KED Global Sites

THE KOREA ECONOMIC DAILY, GLOBAL EDITION

SIGN IN
JOIN

Companies
Korean Investors
- Korean Investors Home
- Best Asset Managers by Korean Investors
Deals
- M&A
- ECM/DCM
Markets
Culture & Trends
Perspectives
Hidden Champions
Future Unicorns

Follow us

Ocrevus

Cookies on KED Global

No articles were found.Please search again.

No articles were found.
Please search again.